Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amicus Therapeutics, Inc. (NASDAQ: FOLD) SEC filings page on Stock Titan provides access to the company’s official disclosures as a rare disease biotechnology issuer. Amicus describes itself as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases, including Fabry disease and late-onset Pompe disease.
Key filings for FOLD include current reports on Form 8-K that summarize material events and financial updates. For example, Amicus has filed 8-K reports to furnish press releases announcing quarterly financial results for periods ended June 30, 2025 and September 30, 2025. These filings identify the company’s common stock as listed on NASDAQ under the symbol FOLD and outline that the information provided under Item 2.02 (Results of Operations and Financial Condition) is furnished rather than filed for certain liability purposes.
Through its periodic reports and exhibits, Amicus details net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), operating expenses, non-GAAP measures and cash position. These documents also describe the company’s focus on rare disease medicines and provide context for its commercial performance and research investments.
Investors can also expect SEC filings related to significant corporate transactions. On December 19, 2025, Amicus and BioMarin Pharmaceutical Inc. announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction, a development that would typically be reflected in transaction-related filings and proxy materials as the process advances, subject to regulatory and stockholder approvals.
On Stock Titan, Amicus filings are supplemented by AI-powered tools that help explain the content and structure of documents such as 8-Ks, quarterly reports and, when available, annual reports and proxy statements. Users can review real-time updates from EDGAR, track how Amicus reports on its rare disease portfolio and commercial performance, and examine the regulatory record that underpins analysis of FOLD as a biotechnology stock.
Amicus Therapeutics, Inc. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer identifying themselves as former large holders. The filing states the Reporting Persons currently beneficially own 0 shares of Amicus common stock (CUSIP 03152W109) representing 0% of the class.
The statement notes the Reporting Persons "have ceased to be the beneficial owner of more than five percent of the class of securities." The filing lists the Reporting Persons' business address and is signed by Paul J. Glazer on 05/01/2026.
Amicus Therapeutics ownership update: Vanguard Capital Management reports beneficial ownership of 16,350,837 shares of common stock, representing 5.20% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 16,350,837 shares and sole voting power for 2,327,280 shares. The form clarifies the reported holdings reflect securities managed across Vanguard Capital Management LLC and specified affiliates.